AI-64310-CRFT

Translational Research Webinars

WB64292: Routine Measurement: New Methods and Workflows for Translational Clinical Research

Mass spectrometry (MS) has been universally applied for biomarker discovery, but only recently is becoming a

fixture in clinical research labs. New MS technologies have accelerated the collection of high quality, deep data from

complex samples, but workflows for analyzing and efficiently processing these data have lagged behind the hardware

improvements. In this webinar we will discuss complete workflows that integrate data from discovery and targeted

quantification experiments to streamline and simplify translational clinical research.

WB64305: Biomarker Discovery: Translating Proteomics into Clinical Diagnostics

In this webinar Dr Eleftherios P. Diamandis and Dr. Andrei P. Drabovich of Mount Sinai Hospital will discuss integration

of -omics technologies for a selection of biomarker candidates, and focus on mass spectrometry as a principal

technique for qualitative and quantitative analysis of proteins. Proteomic profiling of tissues, proximal fluids and cell

lines as well as development of quantitative selected reaction monitoring (SRM) assays will be discussed.

WB64307: Clinical Applications of LC-MS: Development and Research Application of a Highly Sensitive LC-MS

Method for Quantification of a Cholesterol Protein in Plasma

The topic of this webinar is Proprotein convertase subtilisin/kexin type 9 (PCSK9) a key player in the regulation

of circulating low-density lipoprotein cholesterol (LDL-C). Both the distinct forms observed in plasma and

posttranslational modifications (PTMs) described in cell-based studies are likely to affect its function and thereby

LDL-C levels. ELISA kits are available for quantification, but inherently lack the discriminative power to resolve isoforms

and PTMs. To address this issue, and given the complexity and wide dynamic range of the plasma proteome, we have

developed and applied a Mass Spectrometry ImmunoAssay-Selected Reaction Monitoring (MSIA-SRM) method to

quantify PCSK9. This web seminar will explain the development and validation of the method, including the sample

preparation techniques.

WB64011: LC/MS - More Analytically Sensitive and Specific for Subtyping Proteins in Clinical Research

Protein subtyping by LC/MS offers unique advantages. It is not limited by antibody availability and is able to identify

the entire proteome at a single analysis with high sensitivity and specificity. We have successfully developed a novel

method for subtyping amyloid proteins using the Thermo Scientific™ Q Exactive™ Mass Spectrometer. This clinical

research method offers high sensitivity and specificity for identifying amyloid proteins and will be the focus of the

discussion in this video.

WB64010: Development of Multiplexed MSIA (Mass Spectrometric Immunoassay)-SRM Methods for Proteins

Associated with Alzheimer’s Disease and Application to Plasma Samples

One of the biggest challenges in the translation of mass spectrometry (MS)-based biomarkers into the development

of clinical research methods is the lack of fully developed tools and workflows to deliver the throughput specificity,

sensitivity, and robustness needed for clinical applications. Immunoenrichment coupled to selected-reaction

monitoring (MSIA-SRM) allows high-throughput, quantitative and highly selective detection of clinically important

proteins in plasma, serum and cerebrospinal fluid. In this video, the crucial parameters that must be considered when

developing MSIA-SRM assays are discussed, along with how this method has been applied to the study of Alzheimer’s

Disease plasma samples in a series of studies.

For research use only. Not for use in diagnostic procedures.